Abrysvo, the first vaccine administered during pregnancy to prevent RSV among infants, was approved Monday, Aug. 21 by the U.S. Food and Drug Administration. It was found to be nearly 82% effective at reducing the risk of severe lower respiratory tracts during a clinical trial. After RSV overwhelmed hospitals in 2022, there are now two RSV vaccines for older adults, a preventative drug for young children, and Abrysvo now available.
Source link
RSV vaccine for babies, given to their mothers during pregnancy, receives FDA approval
Published on